TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02995057

Intervention type: DEVICE
Intervention: Gold- or silver-coated, or uncoated nickel microneedles
Description: The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
Study: NCT02808065

Intervention type: DRUG
Intervention: Tacrolimus
Description: Administered dose were individualized according to their own prescription

Intervention type: DRUG
Intervention: Mycophenolate mofetil
Description: Administered dose were individualized according to their own prescription
Study: NCT00339768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/omeprazole
Description: To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/omeprazole
Description: To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/omeprazole
Description: To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
Study: NCT00604500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
Description: MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
Study: NCT01619800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blended Sensor Optimization (BSO)
Description: At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Accelerometer Alone (AA)
Description: Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
Study: NCT01357707

Intervention type: GENETIC
Intervention: DNA preparation
Description: Taking blood or saliva from the patient to prepare DNA therefrom
Study: NCT05777707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Description: PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Nedaplatin
Description: Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
Study: NCT01938482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% GSK1940029 gel
Description: Will be supplied as gel for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% GSK1940029 gel
Description: Will be supplied as gel for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% GSK1940029 gel
Description: Will be supplied as gel for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% GSK1940029 gel
Description: Will be supplied as gel for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3%/1% vehicle gel only
Description: Will be supplied as gel for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3%/1% vehicle gel only
Description: Will be supplied as gel for topical application
Study: NCT03263637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4573
Description: AZD4573 will be administered as a intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4573
Description: AZD4573 will be administered as a intravenous (IV) infusion.
Study: NCT01212874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Description: nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esmolol
Description: esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
Study: NCT00378690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprorelin acetate
Description: LHRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin acetate
Description: LHRH antagonist
Study: NCT01624064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 2.5-20 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 2.5-20 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Supplement
Description: Calcium 2.5-20 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Supplement
Description: Calcium 2.5-20 mg/day
Study: NCT01038856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
Study: NCT03648944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Rehabillitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Accelerated Rehabillitation
Study: NCT01494506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 Fluorouracil
Description: Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks
Study: NCT01598701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
Study: NCT02375503

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00869180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Topical diclofenac patch applied once daily to area of pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
Study: NCT04139525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8% trisodium citrate
Description: 8% trisodium citrate in the dose of 150 ml/h.
Study: NCT03176485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulator
Description: A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulator
Description: A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
Study: NCT00656617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 12 mg/m\^2 IV over 1 hour daily for 3 days (days 4 to 6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1.5 g/m\^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
Study: NCT03315949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG)
Description: Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Description: Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
Study: NCT01788514

Intervention type: OTHER
Group type: OTHER
Intervention: Videogame
Description: Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
Study: NCT02236377

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
Study: NCT02122419

Intervention type: OTHER
Intervention: lateral
Description: spinal anesthesia performed during lateral position

Intervention type: OTHER
Intervention: sitting
Description: spinal anesthesia performed during sitting position
Study: NCT03079830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramid
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Piritramid
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
Study: NCT00984867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg tablet, oral, once daily, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT01214122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 60 mg orally twice daily for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10 x 2.5 (25) mg orally once daily on day 1 and on day 14
Study: NCT02515786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen humidification
Description: humidification for oxygen delivered by nasal catheter
Study: NCT01374737

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: dexmedetomidine, 0.1ug/kg up or down
Study: NCT01598701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL 0.9% Sodium Chloride
Study: NCT02392793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talazoparib
Description: Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talazoparib
Description: Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given intravenously daily, days 2-6 immediately following the talazoparib dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given intravenously daily, days 2-6 immediately following the talazoparib dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless peg-filgrastim is given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless peg-filgrastim is given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-filgrastim
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless filgrastim is given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-filgrastim
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless filgrastim is given.
Study: NCT04444869

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin injection
Description: Standard dose cisplatin given concurrently with radiation therapy
Study: NCT00564356

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery with phacoemulsification
Description: removal of cataract with phacoemulsification technique
Study: NCT03552406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU104
Description: Intravenous Infusion for 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU104
Description: Intravenous Infusion for 1 hour.
Study: NCT03635125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol I
Description: Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol I
Description: Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol II
Description: Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol II
Description: Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline Washout Phase
Description: 2 to 4 week Baseline Washout Phase
Study: NCT00487669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex, pemetrexed
Description: The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
Study: NCT02569073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol 5 mg, every other night, orally
Study: NCT02569073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo--no drug
Study: NCT01433666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast (EU: Daxas, USA: Daliresp)
Description: Acute intervention: 1 time each dose on different days. Capsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast (EU: Daxas, USA: Daliresp)
Description: Acute intervention: 1 time each dose on different days. Capsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast (EU: Daxas, USA: Daliresp)
Description: Acute intervention: 1 time each dose on different days. Capsulated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute intervention: single administration, capsulated form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: roflumilast
Description: Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
Study: NCT03552406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU104
Description: Intravenous Infusion for 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU104
Description: Intravenous Infusion for 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU104
Description: Intravenous Infusion for 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous Infusion for 1 hour (2 hours at initial dose)
Study: NCT01946867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBTXR3 activated by IMRT
Study: NCT00989300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - rabeprazole
Description: 20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - omeprazole
Description: 20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment C - placebo
Description: placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
Study: NCT01433666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast
Description: Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast
Description: Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
Study: NCT02437292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression with stretching
Study: NCT00415467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GliaSite Radiation Therapy System
Description: Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
Study: NCT02433717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
Study: NCT01777646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
Study: NCT01946945

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing after Blastocyst biopsy
Description: PGD using blastocyst biopsy and testing of the biopsy by NGS
Study: NCT00482833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28).
Study: NCT01433666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast
Description: Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
Study: NCT01301573

Intervention type: BIOLOGICAL
Intervention: rAAV-GAD